| abstract |
Embodiments of the present application relate to compositions of live attenuated alphaviruses and methods for live attenuated alphaviruses. In certain embodiments, a live attenuated virus composition includes, but is not limited to, one or more live attenuated alphaviruses and a composition that reduces inactivation and / or degradation of the live attenuated alphavirus. . In other embodiments, the live attenuated virus composition may be a vaccine composition. In yet other compositions, the live attenuated alphavirus composition may comprise a HEPES buffer. In other embodiments, the HEPES buffer may further comprise carbohydrate and gelatin and / or salt. |